Matthew N Hurley

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3563725/publications.pdf

Version: 2024-02-01

623734 610901 32 1,022 14 24 citations g-index h-index papers 37 37 37 1636 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A regional evaluation of the health care utilization and outcomes of children and young people with longâ€term ventilation needs. Child: Care, Health and Development, 2021, 47, 70-76.	1.7	O
2	An ex vivo cystic fibrosis model recapitulates key clinical aspects of chronic Staphylococcus aureus infection. Microbiology (United Kingdom), 2021, 167, .	1.8	12
3	Adenotonsillectomy in children. Paediatrics and Child Health (United Kingdom), 2020, 30, 1-5.	0.4	2
4	Life-threatening hypersensitivity pneumonitis secondary to e-cigarettes. Archives of Disease in Childhood, 2020, 105, 1114-1116.	1.9	31
5	Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis. The Cochrane Library, 2020, 2020, CD008037.	2.8	2
6	A systematic Cochrane Review of antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis. Paediatric Respiratory Reviews, 2020, 36, 109-111.	1.8	0
7	Fifteen-minute consultation: An evidence-based approach to the child with preschool wheeze. Archives of Disease in Childhood: Education and Practice Edition, 2018, 103, 7-14.	0.5	4
8	Early Respiratory Bacterial Detection and Antistaphylococcal Antibiotic Prophylaxis in Young Children with Cystic Fibrosis. Annals of the American Thoracic Society, 2018, 15, 42-48.	3.2	24
9	The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers. Thorax, 2018, 73, 388-390.	5.6	181
10	Staphylococcus aureus in cystic fibrosis. Current Opinion in Pulmonary Medicine, 2018, 24, 586-591.	2.6	14
11	Staphylococcus aureus in cystic fibrosis: problem bug or an innocent bystander?. Breathe, 2018, 14, 87-90.	1.3	24
12	Percutaneous lines for delivering intravenous antibiotics in people with cystic fibrosis. The Cochrane Library, 2017, 2017, CD008243.	2.8	1
13	Where Are We Now with the Role of Steroids in the Management of Bronchopulmonary Dysplasia in Extremely Premature Babies?. Frontiers in Pediatrics, 2016, 4, 85.	1.9	0
14	Bronchopulmonary Dysplasia Within and Beyond the Neonatal Unit. Advances in Neonatal Care, 2016, 16, 17-25.	1.1	17
15	Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis. The Cochrane Library, 2015, , CD009650.	2.8	35
16	Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis. The Cochrane Library, 2015, , CD009730.	2.8	19
17	Optimising respiratory health in children with cystic fibrosis. Paediatrics and Child Health (United) Tj ETQq1 1 0.	7843]4 rg 0.4	gBT ∤Overlock
18	Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis. Paediatric Respiratory Reviews, 2015, 16, 246-248.	1.8	5

#	Article	IF	CITATIONS
19	Rate of improvement of CF life expectancy exceeds that of general populationâ€"Observational death registration study. Journal of Cystic Fibrosis, 2014, 13, 410-415.	0.7	66
20	Interventions for the eradication of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) in people with cystic fibrosis., 2013,, CD009650.		10
21	New agents to treat lung infection in cystic fibrosis: a big enough leap?. Future Medicinal Chemistry, 2013, 5, 117-120.	2.3	0
22	Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis. The Cochrane Library, 2013, , CD008037.	2.8	18
23	Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study. BMJ: British Medical Journal, 2012, 344, d7373-d7373.	2.3	235
24	Fluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosis. Therapeutic Advances in Respiratory Disease, 2012, 6, 363-373.	2.6	7
25	Novel approaches to the treatment ofPseudomonas aeruginosainfections in cystic fibrosis. European Respiratory Journal, 2012, 40, 1014-1023.	6.7	100
26	Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis. Paediatric Respiratory Reviews, 2012, 13, 160-161.	1.8	1
27	Optimizing respiratory health in children with cystic fibrosis. Paediatrics and Child Health (United) Tj ETQq $1\ 1\ 0$.	784314 rg 0.4	;BT _d Overloc <mark>k</mark>
28	A Glycopeptide Dendrimer Inhibitor of the Galactoseâ€Specific Lectin LecA and of ⟨i⟩Pseudomonas aeruginosa⟨/i⟩ Biofilms. Angewandte Chemie - International Edition, 2011, 50, 10631-10635.	13.8	149
29	Treatment massive haemoptysis in cystic fibrosis with tranexamic acid. Journal of the Royal Society of Medicine, 2011, 104, 49-52.	2.0	17
30	Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis., 2010,, CD008037.		6
31	Patients' blogs—do doctors have anything to fear?. BMJ: British Medical Journal, 2007, 335, 645-646.	2.3	7

Antibiotics for chronic pulmonary infection in children with a neurodisability (neurodevelopmental) Tj ETQq0 0 0 rg $\frac{87}{2.8}$ /Overlock 10 Tf 50 for chronic pulmonary infection in children with a neurodisability (neurodevelopmental) Tj ETQq0 0 0 rg $\frac{87}{2.8}$ /Overlock 10 Tf 50 for chronic pulmonary infection in children with a neurodisability (neurodevelopmental) Tj ETQq0 0 0 rg $\frac{87}{2.8}$ /Overlock 10 Tf 50 for chronic pulmonary infection in children with a neurodisability (neurodevelopmental) Tj ETQq0 0 0 rg $\frac{87}{2.8}$ /Overlock 10 Tf 50 for chronic pulmonary infection in children with a neurodisability (neurodevelopmental) Tj ETQq0 0 0 rg $\frac{87}{2.8}$ /Overlock 10 Tf 50 for chronic pulmonary infection in children with a neurodisability (neurodevelopmental) Tj ETQq0 0 0 rg $\frac{87}{2.8}$ /Overlock 10 Tf 50 for chronic pulmonary infection in children with a neurodisability (neurodevelopmental) Tj ETQq0 0 0 rg $\frac{87}{2.8}$ /Overlock 10 Tf 50 for children with a neurodisability (neurodevelopmental) Tj ETQq0 0 0 rg $\frac{87}{2.8}$ /Overlock 10 Tf 50 for children with a neurodisability (neurodevelopmental) Tj ETQq0 0 0 rg $\frac{87}{2.8}$ /Overlock 10 Tf 50 for children with a neurodisability (neurodevelopmental) Tj ETQq0 0 0 rg $\frac{87}{2.8}$ /Overlock 10 Tf 50 for children with a neurodisability (neurodevelopmental) Tj ETQq0 0 0 rg $\frac{87}{2.8}$

32